What the Marketing of “Vaccine Alternatives” Reveals
In August 2021 — several months after COVID vaccines became available — Florida ran an experiment nobody quite recognized as one. Governor Ron DeSantis opened the first state-run monoclonal antibody sites in the country, pushing Regeneron's antibody cocktail through drive-through clinics and stadium parking lots. By the time the last site opened, Florida had administered more than 130,000 monoclonal treatments, and DeSantis was touring hospitals crediting the antibodies with significant drops in new admissions. This was the same governor fighting vaccine mandates and vaccine passports in court. The message, unstated but unmistakable, was that the antibody was the acceptable form of pharmaceutical intervention and the vaccine was not.
Then, on January 24, 2022, the FDA revoked the emergency authorizations for REGEN-COV and Eli Lilly's bamlanivimab-etesevimab. Omicron had mutated the spike protein enough that both drugs lost clinical value. They still bound the old virus and no longer touched the one circulating. Every Florida monoclonal site went dark. DeSantis called the decision reckless and said the FDA had acted "without a shred of clinical data," and threatened to sue.
While the FDA officially revoked those authorizations it was Omicron that rendered those monoclonal antibodies obsolete. The vaccines, meanwhile, built through a different mechanism — a broad, evolving immune response with T cells and memory B cells, not a single locked-in antibody shape — kept doing what they'd been doing all along: keeping vaccinated people out of the hospital, even against omicron, even without an update. That's the whole story of monoclonal antibodies versus vaccines compressed into one news cycle, and almost nobody draws the right lesson from it.
The lesson matters now because the same dynamic is back, dressed differently — and this time it isn't a governor improvising. It is federal policy.
Most of the current wave of drug-based prevention is a genuine advance and the products are true values. XOCOVA (ensitrelvir), which I've consulted on for its maker Shionogi, is the first drug approved specifically for post-exposure prevention of COVID — take it within 72 hours of a known exposure and trials showed a 67% reduction in symptomatic infection. That's a real tool for a real window: the days between exposure and infection when vaccination, already administered or not, can't retroactively do anything. DoxyPEP — a dose of doxycycline after sex — is now genuine standard of care for preventing bacterial STIs in high-risk populations, though it's a strategy that consumes its own advantage: gonococcal resistance to tetracycline is climbing as uptake rises, with models projecting meaningful efficacy loss within five to twelve years. And lenacapavir as HIV pre-exposure prophylaxis is close to invaluable, because after forty years of trying, there is still no HIV vaccine. Nobody markets doxyPEP as a substitute for a syphilis vaccine, because there is no syphilis vaccine and post-exposure prophylaxis was never trying to do a vaccine's job in the first place. Similarly, travelers have taken malaria chemoprophylaxis for generations; nobody called it a vaccine alternative, because no malaria vaccine existed for it to replace. These tools fill actual voids.
The distinguishing question isn't whether something comes from a needle or a pill or an IV bag. It's whether the product is filling a genuine immunological gap — a hole no vaccine can plug — or an ideological one, giving people a way to look like they're doing something about a preventable disease without doing the one thing that actually prevents it durably.
What's changed is that the federal government is now working both sides of that question at once.
BARDA's mRNA vaccine portfolio, roughly half a billion dollars of it, was cancelled outright; ARPA-H's own chief data officer resigned over the decision. Several vaccines were struck from the CDC's childhood recommendation list. An executive order took aim at MMR. Whatever one thinks of any individual decision, the aggregate effect is not in dispute: a population now exists that wants protection against infectious disease and either cannot get vaccinated or has been told by its own government that it probably shouldn't bother.
That population is not a clinical category. It is a market. And the same government that manufactured it is now funding the supply.
Consider the current director of ARPA-H.
Alicia Jackson, sworn in last October after six years at DARPA, told Fierce Biotech in January that her agency can help make the vaccine controversy a thing of the past — by rendering vaccines obsolete. "It's funny how we always talk about vaccines," she said. "There's actually a multitude of other technologies that you can use to protect people against infectious disease." Her agency has put up to $30 million behind an antibody-generating AI platform at Vanderbilt, part of a broader $204 million effort.
Read as pure biotechnology optimism, none of that is remarkable. Monoclonals are a marvel, longer-acting antibodies are a worthy research goal. Read in context — an administration that has spent a year denigrating vaccines and dismantling the infrastructure that produces them — it is something else. It reframes vaccines as one option among many for which there are alternatives, rather than the platform every other option is usually a narrower complement to. When a private company says that, it's marketing. When the federal research agency says it, it's industrial policy.
Anna Durbin, who directs the Johns Hopkins Center for Immunization Research, put it plainly in the same article: monoclonals have a role, especially for people who cannot receive vaccinations, but they don't trigger immune memory the way vaccines do, so they must be given again and again and again, each time you want protection. For flu, where we vaccinate annually anyway, an antibody may be fine. For measles, mumps, rubella, varicella, polio, vaccination provides long-lived protection that monoclonal antibodies cannot. They are given by infusion. They cost far more.
Add to that what Florida already demonstrated: Evusheld, a pre-exposure monoclonal antibody for the immunocompromised who have suboptimal vaccine responses, was withdrawn in January 2023 when omicron subvariants mutated past its binding site — the exact mechanism that killed the Regeneron and Lilly drugs a year earlier. AstraZeneca's successor, sipavibart, was discontinued after resistance emerged in late-stage trials. Invivyd, another company I have consulted and done press for, took the financial risk of developing and fielding Pemgarda when no other company was willing to chase a shrinking, high-cost, high-liability niche, and Pemgarda is the reason that population has any pre-exposure option at all. They deserve praise and accolades for the successful development of this product. However, an antibody is leased protection: recurring cost, recurring appointment, recurring vulnerability to the virus simply changing shape. Active immunity from a vaccine is a trained capability your own immune system owns outright.
There's an irony worth thinking through. The movement that built its identity on distrust of pharmaceutical dependency is being offered, as its flagship alternative, more highly pharma-dependent products. And the administration promoting antibodies as the way past the vaccine debate has simultaneously put Beyfortus and Enflonsia under FDA scrutiny for perceived safety concerns. Neither is a vaccine. Both, similar to vaccines, are available to be given to healthy infants on a schedule — which appears to be the operative quality that draws fire.
None of this means the products shouldn't exist, or that companies are wrong to build them. A firm facing a regulator that keeps closing its narrower, more defensible lanes is going to find the lane that achieves a return on investment. That's not a scandal; it's what companies do, and I don't fault them for it. Aiming a product at people who "can't, or won't, get vaccinated" is nonetheless fraught, and the two halves of that phrase are not alike. "Can't" is a real population — infants too young for MMR, transplant recipients, patients on B-cell-depleting therapy, people for whom vaccination genuinely doesn't take. "Won't" is not an immunological category. What separates an eligible, unvaccinated child from immunity is a choice, not a biological hole.
The scandal, if there is one, sits upstream. An HHS leadership that spends a year making the word "vaccine" radioactive should expect the market to route around it, and monoclonal antibodies marketed as vaccine alternatives are exactly the kind of routing that predictable policy failure produces. The people who created that arbitrage bear more responsibility for it than the companies cashing it in.
The question to keep asking isn't whether antibody therapies should exist. Of course they should — they're a marvel, and in the populations they were built for, they save real lives. The question is whether we're going to keep letting a preference masquerade as an indication.